UK markets closed

Ironwood Pharmaceuticals, Inc. (IRWD)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
9.64+0.15 (+1.58%)
At close: 4:00PM EDT

Ironwood Pharmaceuticals, Inc.

100 Summer Street
Suite 2300
Boston, MA 02110
United States
617 621 7722

IndustryDrug Manufacturers—Specialty & Generic
Full-time employees317

Key executives

NameTitlePayExercisedYear born
Mr. Mark MallonCEO & Director2.57MN/A1963
Mr. Thomas A. McCourtPres974.02k959.45k1957
Ms. Gina R. Consylman CPACFO, Sr. VP & Treasurer1.1MN/A1973
Mr. Brian M. CaliCo-Founder and Sr. VP of R&D Strategy & External InnovationN/AN/AN/A
Mr. G. Todd MilneCo-Founder and VP of sGC R&DN/AN/AN/A
Mr. Jason RickardCOO & Sr. VP of OperationsN/AN/A1971
Ms. Kelly MacDonaldChief Accounting Officer & VP of Fin.N/AN/AN/A
Ms. Meredith KayaVP of Investor Relations & Corp. CommunicationsN/AN/AN/A
Mr. Conor KilroySr. VP & Gen. CounselN/AN/A1982
Mr. Jonathan RosinSr. VP of HRN/AN/AN/A
Amounts are as of 31 December 2019, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the Canada and European Union; MD-7246, an oral, intestinal, non-opioid, pain-relieving agent for patients suffering from abdominal pain associated with GI diseases; and IW 3718, a gastric retentive formulation of a bile acid sequestrant, which is in Phase III clinical trials for the treatment of GERD. Ironwood Pharmaceuticals, Inc. has collaboration agreements with Allergan plc and AstraZeneca AB to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other gastrointestinal (GI) conditions in North America, China, Hong Kong, Macau, and Japan, as well as a license agreement with Astellas Pharma Inc. to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other GI conditions in Japan. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Boston, Massachusetts.

Corporate governance

Ironwood Pharmaceuticals, Inc.’s ISS governance QualityScore as of 6 October 2020 is 4. The pillar scores are Audit: 2; Board: 1; Shareholder rights: 7; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.